Expert Interview
Examining Oruka Therapeutics’ ORKA-001 Phase 2a EVERLAST-A Trial Results for moderate-to-severe Plaque Psoriasis
Ticker(s): ORKA, JNJ, ABBV, BMY, NVS, AMGN, TAKInstitution: Aimee Payne Lab, Columbia University Irving Medical Center and Philipps University of Marburg and Charité
Associate Research Scientist & Dermatologist with a research focus on inflammatory and autoimmune skin diseases and T-cell immunology
Manages 300-400 patients per month with atopic dermatitis.
Work centered on immune-mediated mechanisms of skin disease, particularly T-cell immunology and antigen-specific immune responses, and he actively collaborates within the Payne lab to advance antigen-specific immunotherapies and translational research on autoimmune skin disorders.
What impact could once-yearly dosing have on patient adherence and long-term treatment use?
Added By: dami_adminHow meaningful are the ORKA-001 Phase 2a efficacy results compared with currently available psoriasis biologics?
Added By: dami_adminWhat additional clinical data would you need to see before considering ORKA-001 a potential market-leading therapy?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
